Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-Blind, Multicenter, Parallel, Comparative, Randomized, Phase IV Clinical Trial for the Clinical Evaluation of the Quality of Life of the Subject, the Efficacy and the Tolerance of Duac Gel (Gel With Clindamycin Phosphate [Equivalent to 1% Clindamycin] and 5% Benzoyl Peroxide) Against Differin Gel (Gel With 0.1% Adapalene) in the Topical Treatment of Mild to Moderate Acne Vulgaris.

Trial Profile

Single-Blind, Multicenter, Parallel, Comparative, Randomized, Phase IV Clinical Trial for the Clinical Evaluation of the Quality of Life of the Subject, the Efficacy and the Tolerance of Duac Gel (Gel With Clindamycin Phosphate [Equivalent to 1% Clindamycin] and 5% Benzoyl Peroxide) Against Differin Gel (Gel With 0.1% Adapalene) in the Topical Treatment of Mild to Moderate Acne Vulgaris.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Jun 2011 Additional company added in associations field.
  • 13 Dec 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top